Invest in Quorum X Diagnostics

The first 4-minute at-home Antigen test for COVID

EARLY BIRD TERMS: $14,250 LEFT

$35,750

reserved of a $350,000 goal

INVEST

min $100

INVESTMENT TERMS

$25M$20Mvaluation cap Future Equity

Early Bird Bonus: First $50K will invest in a SAFE with a $20M valuation cap and 20% discount.

$250, $500, $1K, $10K

LEAD INVESTOR

Covid19 has changed all of our lives. Even as vaccines are widely available, there is still a significant need for rapid testing at long term care facilities, sporting events, cruise ships, internationally, and a multitude of other applications. COVIDNOW can meet this need. In addition to Covid19, the technology that Maria and her team have developed could potentially be applied to other conditions, such as the test for Pseudomonal Pneumonia. Can you envision a future where people can quickly and cheaply test for various ailments as opposed to lengthy, tedious, expensive doctor's visits or blood work? I can; Quorum X Diagnostics has that potential. Further, having talked with Maria on multiple occasions, it is clear she is deeply passionate about Quorum X Diagnostics and their mission. This is in addition to her being a brilliant scientist, sophisticated businesswoman, and great leader. She and her team have proven their ability to execute over the past year, and I am confident that she will continue to do so. Together, we can enhance the world (and potentially earn a sizeable return, evidenced by Quorum X Diagnostic's significant increase in valuation since the last round). Will you join us?

Pitch Video

Investor Panel

quorumxdiagnostics.com

Atlanta GA

Technology Bio Tech Hard Tech Medical Device Life Science

Highlights

💸 $630K raised in 2020, $100K raised in 2021 thus far ($70K Private, $30K Wefunder)

💥 We went from idea to a Covid product to FDA application in under a year.

🔬Tested 350+ patient samples, results confirmed by 2 independent labs

👩🏻‍⚕️ Team consists of 5 doctors & an Army of interns

💰 3 established Go-To-Market Strategies & National distribution with help of Physician 360.

📌 Anticipated Market Demand of 60-90M tests weekly

Our Team

Global need. We realized we could use the same unique technology (that was used to build our QXD-1 Fast test for Pseudomonal Pneumonia) and use it to build a test for COVID.

The first 4-minute at-home Antigen test for COVID

We are 'testing the waters' to gauge investor interest in an offering under Regulation Crowdfunding. No money or other consideration is being solicited. If sent, it will not be accepted. No offer to buy securities will be accepted. No part of the purchase price will be received until a Form C is filed and only through Wefunder’s platform. Any indication of interest involves no obligation or commitment of any kind. Presently, we are only taking Reservations! This means right now no monies will be taken, however; you can reserve your investment now. It is only when we hit 50K raised and file our schedule C paperwork and go live. At that point Wefunder will send you an update and ask you if you are still interested in investing and to confirm your investment amount. It will only draw funds if you confirm your investment at that time.

HIGHLIGHTS:

The 4-minute COVIDNOW® antigen test currently has the fastest development time compared to competitive products that currently have EUA approval.
COVIDNOW® is SIMPLE. It was designed to be easy to make self-testing at-home a viable option for everyone!
QXD’s COVIDNOW® test is an antigen test vs. an antibody test meaning it can detect active infection.
The sensitivity of the COVIDNOW® test is able to detect an active infection in asymptomatic individuals.
COVIDNOW® does not require a prescription.
The COVIDNOW® APP uses the latest in A.I. technology making it possible to analyze the test cassette result much sharper than that of the naked eye.
The sample from the COVIDNOW® test does not have to be sent off to a lab; it is not a collection kit.
QXD has partnered with Physician 360, a telemedicine service, to provide immediate connectivity to a board-certified physician for a consultation.
The QXD COVIDNOW® at-home test kit has a mobile phone APP that using AI technology and works in conjunction with the telemedicine service.
QXD's partnership with Physician 360, the telemedicine service, provides an additional distribution channel through P360 kiosks located in 1,000+ stores across all 50 states.
All patent applications required for the proprietary technology used to produce QXD’s rapid diagnostic tests have been submitted and are currently pending.
QXD has a clear exit strategy. Within five years continue the development of the proprietary technology and build out the scientific and organizational infrastructure of the business model at which point it would be optimal for a larger corporation to take the vision to the next level.
COVIDNOW® is pending EUA approval

Making an investment is a huge decision and one that we don’t take lightly. Rest assured, we are dedicated, determined, and passionate about what we are doing.

QXD has an amazing team and we're the team to get it DONE!

Downloads

QXD Sept 2021 Deck.pptx